reason report
guidanc achiev upsid potenti less clear
bottom line share trade lower yesterday modest
sale miss -- albeit larg due fx -- limit oper leverag
importantli think guidanc -- call
y/i organ sale growth adjust ep
-- reason achiev given continu momentum
key product think key share perform
next month much predic upsid
just-issu guidanc sourc less clear us
oper leverag anoth key piec stori
compani less consist deliv meaning upsid
fx major culprit us much execut
stori compani complet integr two major acquisit
stj alr drive new product cycl medic
devic busi ramp rep hire activ neuromodul
continu turnaround nutrit busi continu
believ solid fundament think high
convict behind estim upsid go push share
higher increasingli volatil market remain
sidelin given valuat rel still-high expect
uncertainti potenti sale upside/increment margin
expans level
reiter mp pt believ build sustain
growth momentum top-tier sale ep growth trajectori
compel view believ share near full
valuat even yesterday pullback deliv estim
upsid even better execut behind recent upcom new
product launch believ share could appreci
price target appli multipl ep
estim basic line group multipl
outlook higher organ sale growth partial off-set
higher organ ex fx report
reflect higher organ sale growth vs prior estim
off-set neg fx ep estim remain y/i
report faster ep growth driven less interest expens
higher incom rather oper leverag
expect sale y/i oper ep
y/i vs prior estim previous
compani inform svb leerink llc research
revenu mm ep includ stock compens expens exclud amort
medic suppli devic
ep estim
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
rate share market perform price target abbott
like path top-lin growth acceler compani like reinvest
busi complet integr acquisit includ alr stj
deal potenti bolster compani sale ep growth outlook
becom formid player med-tech diagnost even broader offer
believ margin expans continu remain key piec abbott long-term invest
thesi abbott also attract investor look safer defens stock
healthi dividend yield current increasingli volatil market
help sustain current multipl abbott succeed drive meaning margin expans
nutrit busi margin mid-teen level post-split still
go increas cost effici suppli chain manufactur
abbott pipelin also number smaller increment new product launch expect
next year beyond pend acquisit xienc stori
larg play estim basic stabl drug elut stent market share next
year view abbott like less acquisit immedi term follow
two larg acquisit remain sidelin given valuat rel still-high
expect uncertainti potenti sale upside/increment margin expans
expect share trade assum multipl ep
estim basic line large-cap med-tech group
clearli pois drive above-market sale growth next year believ current
valuat alreadi reflect potenti execut risk around new product launch --
heavili depend notabl freestyl libr mri-saf high power devic --
see opportun potenti downsid vs meaning clear-cut upsid
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
cardiovascular neuromodul
cardiovascular neuromodul
total cardiovascular neuromodul
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
cardiovascular neuromodul domest
cardiovascular neuromodul intern
total cardiovascular neuromodul
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
sg sale
 sale
organ sale growth littl less
neg fx impact around
adjust somewhat
adjust ep
impact vast major
somewhat
adjust
partial off-set fx
net interest expens
incom
adjust ep
growth rapid diagnost contribut
neg fx impact littl
use sale baselin
organ growth rapid diagnost
contribut littl slightli
neg fx impact full year
adjust
littl less
adjust ep
growth rapid diagnost contribut
neg fx impact
around
use sale baselin
organ growth rapid diagnost
contribut littl posit fx
impact full year
somewhat
adjust
sale
gain exchang
net interest expens
adjust ep
y/i mid-point
diagnost contribut posit
organ sale growth
fx impact
around
somewhat
sale
use sale baselin
organ growth rapid diagnost
contribut posit fx impact littl
somewhat
adjust
organ sale growth
baselin rapid diagnost
contribut littl posit
somewhat
adjust
fx impact
use sale baselin
organ growth rapid diagnost
contribut posit fx impact littl
somewhat
adjust
stj alr fx impact
gain exchang
net interest expens
adjust ep
y/i mid-point
gain exchang
net interest expens
adjust ep
y/i mid-point
mid singl digit oper ex stj
stj acquisit
mid singl digit oper fx
stj acquisit
mid singl digit oper fx
singl digit oper fx
mid singl digit oper fx
mid-single-digit ex fx mid- hign-
single-digit key emerg market
modest declin epd
low- mid-singl
mid high-single-digit ex fx
low- mid-singl
mid high-single-
digit ex fx
flat rapic
mid high-single-
digit ex fx
low- mid-singl
digit ex fx rapic
mid high-single-digit ex fx
low- mid-singl
mid high-single-
mid high-single-
improv sale
growth around
mid high-singl
growth diabet
sever
double-digit growth
mid- high singl
failur
singl digit declin
rhythm manag
mid-singl digit ex fx
mid-singl digit ex fx
mid-singl
mid-singl digit ex
assess mitraclip
percutan therapi heart
purpos coapt trial confirm safeti effect
mitraclip system treatment moderate-to-sever sever function mitral
regurgit fmr symptomat heart failur subject treat per
standard care determin site local heart team
appropri mitral valv surgeri random control trial provid
opportun strengthen add label claim regard safeti clinic
benefit mitraclip system symptomat heart failur patient
moderate-to-sever sever function mitral regurgit
object studi evalu safeti effect
lva demonstr non-inferior hmii lva hmii use
treatment advanc refractori left ventricular heart failur
lva intend provid hemodynam support patient
advanc refractori left ventricular heart failur either short term support
bridg cardiac transplant btt myocardi recoveri long term
support destin therapi dt intend use insid
outsid hospit
dapt xienc
implant hbr patient
xienc studi prospect singl arm multi-cent open label trial
evalu safeti dual antiplatelet therapi dapt subject high
risk bleed hbr undergo percutan coronari intervent pci
approv xienc famili coronari drug-elut stent
xienc global studi evalu safeti dapt follow
xienc implant hbr patient elig receptor inhibitor
discontinu assess follow-up subject free
myocardi infarct mi repeat coronari revascular stroke stent
thrombosi arc definite/prob within month prior visit least
day stent compliant dapt without
interrupt either aspirin and/or receptor inhibitor consecut
day consid clear discontinu receptor
inhibitor continu aspirin monotherapi follow-up
regist subject follow month post index
procedur data collect xienc global studi compar
histor control hbr subject
approxim subject random investig site
approxim subject target receiv studi devic
septemb present coapt data transcathet cardiovascular
therapeut tct annual meet landmark coapt studi met primari
safeti efficaci endpoint secondari endpoint show treatment
mitraclip plu medic therapi superior medic therapi alon reduc rate
heart failur hospit improv surviv two year therapeut mitral
valv intervent first demonstr posit outcom clinic trial
ail heart failur patient clinic signific secondari mitral regurgit
file
fda approv
on-go plan enrol patient
approxim subject approxim site global regist
y/i
ww growth rate report
point
point
point
point
point
point
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
rapid diagnost reflect sale aler inc acquir oct compar oper growth rate exclud result rapid diagnost
compar oper sale growth exclud impact exchang total abbott medic devic also includ prior year result stj exclud result amo
stj vascular closur busi compar oper sale growth also reflect reduct st jude medic histor sale
